Activation of the EVI-1 oncogene has been reported in acute myeloid leukemia, chronic myeloid leukemia (CML) in blast crisis, and less commonly, in chronic phase (CP) CML patients. We screened an unselected cohort of 75 CP CML patients who had failed imatinib for expression of EVI-1 and sought a correlation with subsequent outcome on the second-generation tyrosine kinase inhibitors dasatinib (n=61) or nilotinib (n=14). The eight patients (10.7%) who expressed EVI-1 transcripts detectable by real-time PCR had significantly lower EFS, PFS and OS than patients with undetectable transcript. The predictive value of EVI-1 expression was validated in an independent cohort. In a multivariate analysis, EVI-1 expression status and the best cytogenetic response obtained on imatinib were the only independent predictors for OS, PFS and EFS. Our data suggest that screening for EVI-1 expression at the time of imatinib failure may predict for response to second line TKI therapy and consequently aid clinical management.
Introduction
Second generation tyrosine kinase inhibitors (2G-TKI) such as dasatinib or nilotinib are efficacious therapies for chronic myeloid leukemia (CML) patients in chronic phase (CP) who have failed imatinib.
1,2 However, more than 50% of patients fail to achieve MCyR on 2G-TKI and a significant proportion of these eventually experience disease progression. [1] [2] [3] As both 2G-TKI and allogeneic stem cell transplantation are possible therapies for patients failing imatinib there is an urgent need for additional factors present at the point of imatinib resistance that predict for responses (or lack of response) to 2G-TKI and would therefore help in management decisions.
The EVI-1 gene at chromosome band 3q26 exhibits a number of properties consistent with its role as an oncogene, and is activated in a subset of most myeloid leukemias, either via rearrangement of chromosome band 3q26, or by other as yet undetermined mechanisms. 4 In acute myeloid leukemia EVI-1 expression has been associated with a poor prognosis, particularly in younger patients. 5, 6 The mechanistic contribution of EVI-1 expression to a more aggressive disease phenotype remains speculative, but may be related to its interaction with several epigenetic regulators, including methyltransferases. 7 EVI-1 activation has also been described in CML blast crisis, and less commonly in CP, but the value of this expression in predicting patient outcome has not been investigated. 8, 9 We therefore sought to investigate the frequency and prognostic value of detectable EVI-1 expression in imatinib-resistant CP CML.
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Materials and methods

Patients
Between April 2005 and July 2008, we studied 75 consecutive patients with CML in CP resistant to imatinib who were treated with dasatinib (n=61) or nilotinib (n=14).
Written informed consent was obtained from all patients before enrolment. Patient characteristics were typical of those with imatinib-treated 'late' CP (Table 1) . No patient harbored a 3q26 rearrangement in the Ph-positive clone, as assessed by conventional cytogenetics and fluorescent in situ hybridisation using an EVI-1 genespecific probe (Kreatech Diagnostics, Netherlands). The median follow up from starting 2G-TKI was 30 months (range 6 to 53); 95% of the patients were followed for at least one year. Dasatinib and nilotinib were administered as previously described.
1-3
Bone marrow morphology and cytogenetics were assessed prior to 2G-TKI therapy and then every 3 months. CP, complete hematological response (CHR), Minor cytogenetic response (MiCyR), MCyR, complete cytogenetic response (CCyR) and major molecular response (MMR) were defined by conventional criteria.
3,10 The 30-month cumulative incidences of MCyR, CCyR and MMR were 59.1%, 55.1% and 25.7% respectively. The 30-month probabilities of overall survival (OS), progressionfree survival (PFS) and event-free survival (EFS) were 90.7%, 88.9% and 86%.
EVI-1 expression
Peripheral blood was collected from the 75 patients before starting treatment with the chosen 2G-TKI. This was approved by the institutional review board of Imperial College London, Hammersmith Hospital. Total RNA was extracted from cells using the automated QIAcube and the RNeasy kit (Qiagen), and was reverse transcribed to 
Statistical Methods
Probabilities of OS, PFS and EFS were calculated using the Kaplan-Meier method.
Univariate and multivariate analyses for the different outcomes were carried out as previously described. 3 The associations between EVI-1 expression and other pretherapy characteristics were studied using the Fisher exact test. P-values were 2-sided and 95% confidence intervals (CI) computed. For personal use only. on September 14, 2017. by guest www.bloodjournal.org From S1). Interestingly, there was no significant association between detectable EVI-1 expression at the start of 2G-TKI therapy and characteristics commonly associated with progression to advanced phase such as clonal cytogenetic evolution (p=1.0), presence of KD mutations (p=0.67), Sokal score at diagnosis (p=0.4) and hematological resistance to imatinib (p=0.43). The CD34 count in the bone trephine and the percentage of blast in the bone marrow was also comparable between patients with (0.8% and 3.9%) and without (1.4% and 3.5%) EVI-1 expression (p=0.9 and p=0.7 respectively).
Results and discussion
EVI
Patients with positive EVI-1 expression at the onset of 2G-TKI therapy had a significantly lower 30 month EFS (43.7 vs 90.6%, p=0.0001), PFS (43.7 vs 93.8%, p<0.0001), OS (47.5 vs 95.2%, p=0.0003) and cumulative incidence of CCyR (12.0% vs 59.7%, p=0.05) (Table 1 and Figure 1A ) than patients without EVI-1 expression.
We performed multivariate analysis for OS, PFS and EFS. Expression of EVI-1
(present or absent) and the achievement of at least a MiCyR during the prior imatinib therapy were the only independent predictors for OS (RR=0.11, CI=0.02-0.58, p=0.009, and RR=5.2, CI=1.03-24.2, p=0.05), PFS (RR=0.07, CI=0.02-0.3, p=0.0003 and RR=4.9, CI=1.2-20.4, p=0.03) and EFS (RR=0.08, CI=0.02-0.3, p=0.0004 and RR=8.1, CI=2.1-30.1 p=0.002).
We validated the prognostic value of EVI-1 using an independent cohort of 28 patients who were treated in the Liverpool Royal University Hospital with nilotinib We repeated the multivariate analysis including the level of cytogenetic response achieved at 3 months. Expression of EV1-1 and the achievement of MiCyR were the only independent predictors for OS (RR=0.09,CI=0.02-0.5, p=0.004 and RR= 8. Significantly, none of the patients in our cohort in whom EVI-1 expression was detected harbored a BCR-ABL1 KD mutation known to confer resistance to 2G-TKIs; this observation should exclude this mechanism as an alternative explanation for their inferior outcome. Retrospective analysis of archived material revealed that EVI-1 expression was not present in diagnostic samples of patients who were later found to express the transcript, but emerged at a median of 31 months after diagnosis (range 15-103 months). We also screened diagnostic samples from a further 23 CML patients, 10 of whom responded to imatinib and 13 did not. None of these samples had detectable EVI-1 expression, suggesting that EVI-1 expression is not commonly present in patients at diagnosis, regardless of subsequent response to imatinib.
We have shown that detection of expression of the EVI-1 oncogene in imatinibresistant CP CML patients at the start of 2G-TKI therapy is a strong predictor for disease progression and shorter survival, and validated this result using an independent cohort. Measurement of EVI-1 expression at the point of imatinib failure may therefore identify patients who would fare badly on a 2G-TKI regimen and might
be better served by early referral for transplant. Our findings also suggest that, in patients who fail to achieve MiCyR after 3 months of 2G-TKI therapy, EVI-1 expression status may help to distinguish those patients with poor disease outcome from those who have a significantly higher chance of long-term progression-free survival.
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